{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T11:10:07Z","timestamp":1770808207616,"version":"3.50.0"},"reference-count":66,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AstraZeneca","award":["AZ-SRP-2022-01"],"award-info":[{"award-number":["AZ-SRP-2022-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Prostate cancer (PC) is the most prevalent cancer in men in Spain. Clinical management depends on the stage\/tumor response to therapy\/therapy availability. Given the limited national data, we analyzed real-world prevalence and management patterns. Methods: This was an observational, retrospective study using electronic medical records from public primary care centers\/hospitals in Spain (BIG-PAC\u00ae database), between 1 June 2014, and 31 December 2021. Adult PC-diagnosed patients were classified into localized PC with no compromised lymph nodes and no metastasis (N0\/M0), locally advanced PC with compromised lymph nodes, no metastasis (N1\/M0), metastatic hormone-sensitive PC (mHSPC), non-metastatic castration-resistant PC (nmCRPC), and metastatic castration-resistant PC (mCRPC, categorized by treatment line). Progression across stages was recorded. All analyses were descriptive and exploratory. Results: A total of 19,224 patients met the inclusion criteria. The five-year PC prevalence was 590 cases\/100,000 males; localized PC was the most prevalent form of cancer (PC[N0\/M0]: 473\/100,000; PC[N1\/M0]: 78\/100,000), followed by mCRPC (16\/100,000), mHSPC (14\/100,000), and nmCRPC (8\/100,000). We further analyzed 5583 patients with progression. Surgery was performed in 61.7% PC (N1\/M0), while radiotherapy was used in 24.3%. Taxanes were used in 52.4% of the mHSPC patients. First prescription options for mCRPC L1 and L2 were androgen receptor pathway inhibitors (55.9% and 49.7%); 44.9% of mCRPC L3 and 83.3% of L4+ (\u22654 treatment lines) patients used taxanes. Analgesics were common in mHSPC, nmCRPC, and mCRPC patients. Few mHSPC patients died without progression (11.6%); 90.2% and 56.2% of the mCRPC patients received first- and second-line treatments, respectively. During follow-up, 2436 patients died. Cardiovascular comorbidities increased with stage. Conclusions: PC management in Spain varies substantially by disease stage. Advanced disease was associated with higher comorbidity burden and reduced survival in mHSPC and mCRPC patients, despite multiple available treatments.<\/jats:p>","DOI":"10.3390\/cancers18040554","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:42:42Z","timestamp":1770640962000},"page":"554","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiology, Comorbidities and Associated Treatments, Therapeutic Management, and Clinical Outcomes in Patients with Prostate Cancer in Spain (SRealProstate): A Real-World Cohort Study"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0178-4567","authenticated-orcid":false,"given":"Angel","family":"Borque-Fernando","sequence":"first","affiliation":[{"name":"Servicio de Urolog\u00eda, Hospital Universitario Miguel Servet, IIS-Arag\u00f3n, 50009 Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-8860","authenticated-orcid":false,"given":"Nuria","family":"Romero-Laorden","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda M\u00e9dica, Hospital Universitario de La Princesa, UAM-Fundaci\u00f3n Instituto Roche de Medicina Personalizada de Precisi\u00f3n, 28006 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7510-5059","authenticated-orcid":false,"given":"Juan Francisco","family":"Rodr\u00edguez-Moreno","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria HM Hospitales, Facultad de Medicina, Universidad San Pablo CEU, 28003 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelia","family":"Alfaro-Oliver","sequence":"additional","affiliation":[{"name":"Medical Department, AstraZeneca Farmac\u00e9utica Spain, 28050 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariela","family":"Beliera-Kiendl","sequence":"additional","affiliation":[{"name":"Medical Department, AstraZeneca Farmac\u00e9utica Spain, 28050 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2050-7517","authenticated-orcid":false,"given":"Elena","family":"Rebollo-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Atrys Health, 28002 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Atrys Health, 28002 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Rubio-Briones","sequence":"additional","affiliation":[{"name":"Servicio de Urolog\u00eda, Hospital VITHAS 9 de Octubre, 46015 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"ref_1","unstructured":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (2023). Las Cifras del C\u00e1ncer en Espa\u00f1a 2023, Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica."},{"key":"ref_2","unstructured":"Red Espa\u00f1ola de Registros de C\u00e1ncer (2025, August 13). Estimaciones de la Incidencia del C\u00e1ncer en Espa\u00f1a. Available online: https:\/\/redecan.org\/storage\/documentation\/442e1d1a-4040-4674-81cf-5e6a67af6458.pdf."},{"key":"ref_3","unstructured":"Cornford, P., Tilki, D., van den Bergh, R.C.N., Eberli, D., De Meerleer, G., De Santis, M., Gillessen, S., Henry, A.M., van Leenders, G.J.L.H., and Oldenburg, J. (2025, January 21\u201324). EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate cancer. Proceedings of the EAU Annual Congress, Madrid, Spain."},{"key":"ref_4","first-page":"228","article-title":"Options for Curative Treatment of Localized Prostate Cancer","volume":"118","author":"Knipper","year":"2021","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_5","first-page":"87","article-title":"Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers","volume":"14","author":"Choi","year":"2022","journal-title":"Res. Rep. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ajur.2018.11.005","article-title":"Metastatic prostate cancer remains incurable, why?","volume":"6","author":"Dong","year":"2019","journal-title":"Asian J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jamaoncol.2020.6973","article-title":"Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4103\/iju.iju_402_21","article-title":"Combination therapy in metastatic castration sensitive prostate cancer: A Systematic review and network meta-analysis","volume":"38","author":"Kumar","year":"2022","journal-title":"Indian J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/cam4.576","article-title":"Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: Retrospective analysis of real-world data","volume":"5","author":"Flaig","year":"2016","journal-title":"Cancer Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canlet.2021.06.010","article-title":"The treatment landscape of metastatic prostate cancer","volume":"519","author":"Yamada","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminoncol.2023.09.003","article-title":"PARP inhibitors for prostate cancer","volume":"51","author":"Longoria","year":"2023","journal-title":"Semin. Oncol."},{"key":"ref_12","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (2022). Ficha Tecnica Pluvicto 1000 mbq\/mL Solucion Inyectable y para Perfusion, Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios."},{"key":"ref_13","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (2024). Informe de Posicionamiento Terap\u00e9utico de Lutecio (177Lu) Vipivotida Tetraxet\u00e1n (Pluvicto\u00ae) en Combinaci\u00f3n con Terapia de Privaci\u00f3n Androg\u00e9nica (TDA) con o sin Inhibidores de la v\u00eda del Receptor Androg\u00e9nico (RA) Indicado para el Tratamiento de Pacientes Adultos con C\u00e1ncer de Pr\u00f3stata Metast\u00e1sico Progresivo Resistente a la Castraci\u00f3n Positivo al Ant\u00edgeno de Membrana Espec\u00edfico de la Pr\u00f3stata (PSMA) que han Recibido Tratamiento con Inhibidores del eje Androg\u00e9nico y Quimioterapia con Taxanos, Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios."},{"key":"ref_14","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (2024). Informe de Posicionamiento Terap\u00e9utico de Talazoparib (Talzenna\u00ae) en Combinaci\u00f3n con Enzalutamida, para el Tratamiento de Pacientes Adultos con C\u00e1ncer de Pr\u00f3stata Metast\u00e1sico Resistente a la Castraci\u00f3n, en los que la Quimioterapia no est\u00e1 Cl\u00ednicamente Indicada, Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios."},{"key":"ref_15","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (2024). Ficha Tecnica Talzenna 0.25 mg Capsulas Duras, Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios."},{"key":"ref_16","unstructured":"Ministerio de Sanidad (2025, May 03). BIFIMED: Buscador de la Informaci\u00f3n Sobre la Situaci\u00f3n de Financiaci\u00f3n de los Medicamentos\u2014Nomencl\u00e1tor de OCTUBRE\u20142025\u2014LUTECIO (177LU) VIPIVOTIDA TETRAXETAN, Available online: https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do?metodo=verDetalle&cn=759982."},{"key":"ref_17","unstructured":"Ministerio de Sanidad (2025, May 03). BIFIMED: Buscador de la Informaci\u00f3n Sobre la Situaci\u00f3n de Financiaci\u00f3n de los Medicamentos\u2014Nomencl\u00e1tor de OCTUBRE\u20142025\u2014ABIRATERONA, Available online: https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do?metodo=verDetalle&cn=762402."},{"key":"ref_18","unstructured":"Ministerio de Sanidad (2025, May 03). BIFIMED: Buscador de la Informaci\u00f3n Sobre la Situaci\u00f3n de Financiaci\u00f3n de los Medicamentos\u2014Nomencl\u00e1tor de OCTUBRE\u20142025\u2014TALAZOPARIB, Available online: https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do?metodo=verDetalle&cn=726297."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11864-016-0438-9","article-title":"Sequencing Treatment for Castration-Resistant Prostate Cancer","volume":"17","author":"Handy","year":"2016","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Leaning, D., Kaur, G., Morgans, A.K., Ghouse, R., Mirante, O., and Chowdhury, S. (2023). Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: Systematic and structured literature reviews. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1240864"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer\u2014Metastatic and\/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","article-title":"Real-world data: Towards achieving the achievable in cancer care","volume":"16","author":"Booth","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_24","unstructured":"European Medicines Agency (2024, November 28). BIG-PAC. Available online: https:\/\/catalogues.ema.europa.eu\/node\/4136\/administrative-details."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S734","DOI":"10.1016\/j.jval.2019.09.1764","article-title":"PMU146 Validation and representativeness of the spanish BIG-PAC database: Integrated computerized medical records for research into epidemiology, medicines and health resource use (real word evidence)","volume":"22","author":"Enriquez","year":"2019","journal-title":"Value Health"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.recesp.2020.09.014","article-title":"Epidemiolog\u00eda y tratamiento de la insuficiencia cardiaca en Espa\u00f1a: Estudio PATHWAYS-HF","volume":"75","author":"Palacios","year":"2022","journal-title":"Rev. Espa\u00f1ola Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40744-024-00743-5","article-title":"Real-World Osteoporosis Treatment Gap and Costs in Spain: Data from Women with a First Fragility Fracture or Diagnosis of Postmenopausal Osteoporosis","volume":"12","author":"Gatell","year":"2025","journal-title":"Rheumatol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.recesp.2024.06.004","article-title":"Risk of severe cardiovascular events following COPD exacerbations: Results from the EXACOS-CV study in Spain","volume":"78","author":"Santos","year":"2025","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Escobar-Cervantes, C., Palacios, B., Villarreal, M., Guti\u00e9rrez, M., Capel, M., Hernandez, I., Garc\u00eda, M., Lledo, L., and Arenillas, J.F. (2025). Clinical and Economic Impact of a First Major Bleeding Event in Non-Anticoagulated Patients in Spain: A 3-Year Retrospective Observational Cohort Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14041377"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.18176\/resp.00095","article-title":"Impact of potential multiple drug-drug interactions on the adverse event profile of patients with hepatitis C treated with pangenotypic direct-acting antivirals in Spain","volume":"26","author":"Turnes","year":"2024","journal-title":"Rev. Esp. Sanid. Penit."},{"key":"ref_31","first-page":"421","article-title":"Prevalence of chronic rhinosinusitis without\/with nasal polyps according to severity in Spain","volume":"62","author":"Mullol","year":"2024","journal-title":"Rhinology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1055\/a-2336-1062","article-title":"Epidemiology, Treatment Patterns, and Cost Analysis of Immune Thrombocytopenia in Spain between 2014 and 2020: A Population-based Study","volume":"8","author":"Alperovich","year":"2024","journal-title":"TH Open"},{"key":"ref_33","first-page":"1041","article-title":"Clinical management and healthcare resource utilization among patients with obstructive hypertrophic cardiomyopathy in Spain: A real-world study","volume":"78","author":"Echeto","year":"2025","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s12094-021-02561-5","article-title":"SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)","volume":"23","author":"Vazquez","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and End Points of Clinical Trials for Patients with Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_37","unstructured":"ICD (2004). ICD-9-CM\u2014International Classification of Diseases, Practice Management. Ninth Revision, Clinical Modification."},{"key":"ref_38","unstructured":"Centers for Disease Control Prevention (2025, May 03). International Classification of Diseases, Tenth Revision (ICD-10), Available online: https:\/\/www.cdc.gov\/nchs\/icd\/icd-10\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/nchs\/icd\/icd10.htm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_40","unstructured":"Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer (2025, May 03). Dimensiones del C\u00e1ncer. Available online: https:\/\/observatorio.contraelcancer.es\/explora\/dimensiones-del-cancer."},{"key":"ref_41","first-page":"1365","article-title":"Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States","volume":"32","author":"Wallace","year":"2021","journal-title":"Cancer Causes Control"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2147\/CMAR.S506423","article-title":"Real-World Treatment Patterns and Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Insights from a Retrospective Cohort Study","volume":"17","author":"Tashkandi","year":"2025","journal-title":"Cancer Manag. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.euo.2023.12.013","article-title":"Clinical Outcomes of Patients with High-risk Metastatic Hormone-na\u00efve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study","volume":"7","author":"Miyake","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11523-022-00899-6","article-title":"Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry","volume":"17","author":"Verry","year":"2022","journal-title":"Target. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.euros.2024.06.010","article-title":"Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First- to Sixth- line Metastatic Castration-resistant Prostate Cancer Patients","volume":"66","author":"Wenzel","year":"2024","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment Patterns and Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41391-024-00816-0","article-title":"Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-na\u00efve patients with metastatic castration-resistant prostate cancer","volume":"27","author":"George","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/ejhpharm-2021-002798","article-title":"Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: Which patients benefit most?","volume":"30","year":"2023","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/oncolo\/oyad045","article-title":"Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study","volume":"28","author":"Barata","year":"2023","journal-title":"Oncologist"},{"key":"ref_52","unstructured":"Committee for Medicinal Products for Human Use (CHMP), and European Medicines Agency (2025, May 03). Summary of Opinion (Post Authorisation) Zytiga Abiraterone Acetate, Available online: www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-zytiga_en.pdf-0."},{"key":"ref_53","unstructured":"Committee for Medicinal Products for Human Use (CHMP), and European Medicines Agency (2025, May 03). Summary of Opinion (Post Authorisation) Docetaxel Zentiva, Available online: www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-docetaxel-zentiva-ws-1550_en.pdf."},{"key":"ref_54","unstructured":"Committee for Medicinal Products for Human Use (CHMP), and European Medicines Agency (2025, May 03). Summary of Opinion (Post Authorisation) Erleada Apalutamide, Available online: www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-erleada-ii-01_en.pdf."},{"key":"ref_55","unstructured":"Committee for Medicinal Products for Human Use (CHMP), and European Medicines Agency (2025, May 03). Summary of Opinion (Post Authorisation) Xtandi Enzalutamide, Available online: www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-xtandi-ii-47-g_en.pdf."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1007\/s12325-022-02073-w","article-title":"Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan","volume":"39","author":"Leith","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","article-title":"Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology","volume":"75","author":"Nuhn","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_59","unstructured":"Spratt, D., Srinivas, S., Schaeffer, E.M., Adra, N., Ahmed, B., An, Y., Bitting, R., Chapin, B., Cheng, H.H., and Cho, S.Y. (2025). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Prostate Cancer, NCCN."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2011-0364","article-title":"The European Medicines Agency Review of Cabazitaxel (Jevtana\u00ae) for the Treatment of Hormone-Refractory Metastatic Prostate Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use","volume":"17","author":"Pean","year":"2012","journal-title":"Oncologist"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2014.11.033","article-title":"Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer","volume":"67","author":"Kweldam","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/pros.23967","article-title":"Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines","volume":"80","author":"Shore","year":"2020","journal-title":"Prostate"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s11886-023-01909-3","article-title":"Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer","volume":"25","author":"Ng","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e13932","DOI":"10.1111\/eci.13932","article-title":"Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy","volume":"53","author":"Chan","year":"2023","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2011.38.8850","article-title":"Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer","volume":"30","author":"Smith","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Benchimol, E.I., Smeeth, L., Guttmann, A., Harron, K., Moher, D., Petersen, I., S\u00f8rensen, H.T., von Elm, E., and Langan, S.M. (2015). The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med., 12.","DOI":"10.1371\/journal.pmed.1001885"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/554\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:18:58Z","timestamp":1770787138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":66,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18040554"],"URL":"https:\/\/doi.org\/10.3390\/cancers18040554","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}